Copyright
©The Author(s) 2021.
World J Hepatol. Nov 27, 2021; 13(11): 1743-1752
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1743
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1743
Figure 1 Patients in group I distribution among different treatment regimen.
SOFO: Sofosbuvir; DACLA: Daclatasvir; RIBA: Ribavirin; PEG INFS: Pegylated interferon.
- Citation: Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021; 13(11): 1743-1752
- URL: https://www.wjgnet.com/1948-5182/full/v13/i11/1743.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i11.1743